{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:14:03Z","timestamp":1795061643710,"version":"4.10.2"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychol"],"DOI":"10.1186\/s40359-025-03935-y","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T05:46:54Z","timestamp":1767419214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Reza","family":"Moshfeghinia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mostafavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia","family":"Jazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasamin","family":"Khosravaninezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosshi","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshid","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Pasalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"3935_CR1","doi-asserted-by":"crossref","unstructured":"Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A et al. The therapeutic potential of psilocybin. Molecules. 2021;26(10).","DOI":"10.3390\/molecules26102948"},{"issue":"10","key":"3935_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","volume":"73","author":"DE Nichols","year":"2020","unstructured":"Nichols DE. Psilocybin: from ancient magic to modern medicine. J Antibiot. 2020;73(10):679\u201386.","journal-title":"J Antibiot"},{"issue":"5","key":"3935_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and Psychedelic-Assisted psychotherapy. Am J Psychiatry. 2020;177(5):391\u2013410.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"3935_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00213-021-06027-y","volume":"239","author":"N Schimmel","year":"2022","unstructured":"Schimmel N, Breeksema JJ, Smith-Apeldoorn SY, Veraart J, van den Brink W, Schoevers RA. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. Psychopharmacology. 2022;239(1):15\u201333.","journal-title":"Psychopharmacology"},{"key":"3935_CR5","doi-asserted-by":"crossref","unstructured":"Goel DB, Zilate S. Potential therapeutic effects of psilocybin: A systematic review. Cureus. 2022;14(10).","DOI":"10.7759\/cureus.30214"},{"issue":"1","key":"3935_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","volume":"49","author":"RJ Dinis-Oliveira","year":"2017","unstructured":"Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. 2017;49(1):84\u201391.","journal-title":"Drug Metab Rev"},{"key":"3935_CR7","doi-asserted-by":"publisher","first-page":"1040217","DOI":"10.3389\/fpsyt.2022.1040217","volume":"13","author":"CA MacCallum","year":"2022","unstructured":"MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front Psychiatry. 2022;13:1040217.","journal-title":"Front Psychiatry"},{"issue":"2","key":"3935_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol (Oxford England). 2022;36(2):151.","journal-title":"J Psychopharmacol (Oxford England)"},{"issue":"11","key":"3935_CR9","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol (Oxford England). 2014;28(11):983\u201392.","journal-title":"J Psychopharmacol (Oxford England)"},{"issue":"1","key":"3935_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","volume":"43","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term Follow-up of Psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abus. 2017;43(1):55.","journal-title":"Am J Drug Alcohol Abus"},{"issue":"10","key":"3935_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following Psilocybin-Assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry. 2022;79(10):953\u201362.","journal-title":"JAMA Psychiatry"},{"key":"3935_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jad.2021.09.041","volume":"296","author":"NX Li","year":"2022","unstructured":"Li NX, Hu YR, Chen WN, Zhang B. Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. J Affect Disord. 2022;296:26\u201334.","journal-title":"J Affect Disord"},{"key":"3935_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jad.2019.07.076","volume":"258","author":"S Muttoni","year":"2019","unstructured":"Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: A systematic review. J Affect Disord. 2019;258:11\u201324.","journal-title":"J Affect Disord"},{"issue":"3","key":"3935_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","volume":"24","author":"F Tyl\u0161","year":"2014","unstructured":"Tyl\u0161 F, P\u00e1len\u00ed\u010dek T, Hor\u00e1\u010dek J. Psilocybin\u2013summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014;24(3):342\u201356.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"3935_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","volume":"34","author":"GI Agin-Liebes","year":"2020","unstructured":"Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Pont\u00e9 KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155\u201366.","journal-title":"J Psychopharmacol"},{"issue":"15","key":"3935_CR16","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1002\/cncr.31539","volume":"124","author":"W Breitbart","year":"2018","unstructured":"Breitbart W, Pessin H, Rosenfeld B, Applebaum AJ, Lichtenthal WG, Li Y, et al. Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: A randomized controlled trial in patients with advanced cancer. Cancer. 2018;124(15):3231\u20139.","journal-title":"Cancer"},{"issue":"7","key":"3935_CR17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41380-019-0595-x","volume":"25","author":"YH Wang","year":"2020","unstructured":"Wang YH, Li JQ, Shi JF, Que JY, Liu JJ, Lappin JM, et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020;25(7):1487\u201399.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"3935_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12904-022-01034-y","volume":"21","author":"L Mihic-Gongora","year":"2022","unstructured":"Mihic-Gongora L, Jim\u00e9nez-Fonseca P, Hernandez R, Gil-Raga M, Pacheco-Barcia V, Manzano-Fern\u00e1ndez A, et al. Psychological distress and resilience in patients with advanced cancer during the Covid-19 pandemic: the mediating role of spirituality. BMC Palliat Care. 2022;21(1):146.","journal-title":"BMC Palliat Care"},{"issue":"4","key":"3935_CR19","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s10943-014-9864-9","volume":"54","author":"B Garssen","year":"2015","unstructured":"Garssen B, Uwland-Sikkema NF, Visser A. How spirituality helps cancer patients with the adjustment to their disease. J Relig Health. 2015;54(4):1249\u201365.","journal-title":"J Relig Health"},{"issue":"3","key":"3935_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/07347332.2021.1990184","volume":"40","author":"HR Haokip","year":"2022","unstructured":"Haokip HR, Chauhan H, Rawat I, Mehra J, Jyoti J, Sharma K, et al. Relationship between spirituality and depression among patients with malignant cancer at a selected tertiary care Institute - A study from North India. J Psychosoc Oncol. 2022;40(3):331\u201346.","journal-title":"J Psychosoc Oncol"},{"issue":"4","key":"3935_CR21","doi-asserted-by":"publisher","first-page":"E150","DOI":"10.1188\/12.CJON.E150-E155","volume":"16","author":"P Richardson","year":"2012","unstructured":"Richardson P. Assessment and implementation of spirituality and religiosity in cancer care: effects on patient outcomes. Clin J Oncol Nurs. 2012;16(4):E150\u20135.","journal-title":"Clin J Oncol Nurs"},{"issue":"12","key":"3935_CR22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165\u201380.","journal-title":"J Psychopharmacol"},{"issue":"12","key":"3935_CR23","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"3935_CR24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/PSY.0000000000000942","volume":"83","author":"J Walker","year":"2021","unstructured":"Walker J, Mulick A, Magill N, Symeonides S, Gourley C, Burke K, et al. Major depression and survival in people with cancer. Psychosom Med. 2021;83(5):410.","journal-title":"Psychosom Med"},{"issue":"4","key":"3935_CR25","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3892\/ol.2015.2944","volume":"9","author":"HR Smith","year":"2015","unstructured":"Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment (review). Oncol Lett. 2015;9(4):1509\u201314.","journal-title":"Oncol Lett"},{"key":"3935_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctrv.2017.03.012","volume":"56","author":"T Okuyama","year":"2017","unstructured":"Okuyama T, Akechi T, Mackenzie L, Furukawa TA. Psychotherapy for depression among advanced, incurable cancer patients: A systematic review and meta-analysis. Cancer Treat Rev. 2017;56:16\u201327.","journal-title":"Cancer Treat Rev"},{"key":"3935_CR27","doi-asserted-by":"crossref","unstructured":"Dawood Hristova JJ, P\u00e9rez-Jover V. Psychotherapy with Psilocybin for Depression: Systematic Review. Behavioral sciences (Basel, Switzerland). 2023;13(4).","DOI":"10.3390\/bs13040297"},{"issue":"1","key":"3935_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"3935_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/08980101211039086","volume":"40","author":"RH Lehto","year":"2022","unstructured":"Lehto RH, Miller M, Sender J. The role of Psilocybin-Assisted psychotherapy to support patients with cancer: A critical scoping review of the research. J Holist Nursing: Official J Am Holist Nurses\u2019 Association. 2022;40(3):265\u201380.","journal-title":"J Holist Nursing: Official J Am Holist Nurses\u2019 Association"},{"key":"3935_CR30","doi-asserted-by":"crossref","unstructured":"Yu CL, Liang CS, Yang FC, Tu YK, Hsu CW, Carvalho AF et al. Trajectory of antidepressant effects after Single- or Two-Dose administration of psilocybin: A systematic review and multivariate Meta-Analysis. J Clin Med. 2022;11(4).","DOI":"10.3390\/jcm11040938"},{"key":"3935_CR31","doi-asserted-by":"crossref","unstructured":"Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res. 2020;284.","DOI":"10.1016\/j.psychres.2020.112749"},{"issue":"4","key":"3935_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/09540261.2018.1482261","volume":"30","author":"S Ross","year":"2018","unstructured":"Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry (Abingdon). 2018;30(4):317\u201330.","journal-title":"Int Rev Psychiatry (Abingdon)"},{"issue":"10","key":"3935_CR33","doi-asserted-by":"publisher","first-page":"958","DOI":"10.30773\/pi.2021.0209","volume":"18","author":"CL Yu","year":"2021","unstructured":"Yu CL, Yang FC, Yang SN, Tseng PT, Stubbs B, Yeh TC, et al. Psilocybin for End-of-Life anxiety symptoms: A systematic review and Meta-Analysis. Psychiatry Invest. 2021;18(10):958\u201367.","journal-title":"Psychiatry Invest"},{"key":"3935_CR34","doi-asserted-by":"crossref","unstructured":"White CM, Weisman N, Dalo J. Psychedelics for patients with cancer: A comprehensive literature review. Annals Pharmacotherapy. 2023;57(9).","DOI":"10.1177\/10600280221144055"},{"issue":"3","key":"3935_CR35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11864-022-00954-4","volume":"23","author":"N Bates","year":"2022","unstructured":"Bates N, Bello JK, Osazuwa-Peters N, Sullivan MD, Scherrer JF. Depression and Long-Term prescription opioid use and opioid use disorder: implications for pain management in cancer. Curr Treat Options Oncol. 2022;23(3):348\u201358.","journal-title":"Curr Treat Options Oncol"},{"key":"3935_CR36","unstructured":"Schipper S, Nigam K, Schmid Y, Piechotta V, Ljuslin M, Beaussant Y et al. Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. (1469-493X (Electronic))."},{"issue":"7","key":"3935_CR37","doi-asserted-by":"publisher","first-page":"908","DOI":"10.5306\/wjco.v15.i7.908","volume":"15","author":"H Bader","year":"2024","unstructured":"Bader H, Farraj H, Maghnam J, Abu Omar Y. Investigating the therapeutic efficacy of psilocybin in advanced cancer patients: A comprehensive review and meta-analysis. World J Clin Oncol. 2024;15(7):908\u201319.","journal-title":"World J Clin Oncol"},{"issue":"1","key":"3935_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Reviews. 2021;10(1):1\u201311.","journal-title":"Syst Reviews"},{"key":"3935_CR39","doi-asserted-by":"crossref","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. 2008.","DOI":"10.1002\/9780470712184"},{"key":"3935_CR40","doi-asserted-by":"crossref","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366.","DOI":"10.1136\/bmj.l4898"},{"key":"3935_CR41","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355.","DOI":"10.1136\/bmj.i4919"},{"issue":"1","key":"3935_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):1\u201310.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"3935_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","volume":"4","author":"S Ross","year":"2021","unstructured":"Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, et al. Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer. ACS Pharmacol Translational Sci. 2021;4(2):553\u201362.","journal-title":"ACS Pharmacol Translational Sci"},{"key":"3935_CR44","doi-asserted-by":"crossref","unstructured":"Lewis BR, Garland EL, Byrne K, Durns T, Hendrick J, Beck A et al. HOPE: A pilot study of psilocybin enhanced group psychotherapy in patients with cancer. J Pain Symptom Manag. 2023.","DOI":"10.1016\/j.jpainsymman.2023.06.006"},{"key":"3935_CR45","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jad.2022.11.046","volume":"323","author":"S Shnayder","year":"2023","unstructured":"Shnayder S, Ameli R, Sinaii N, Berger A, Agrawal M. Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients. J Affect Disord. 2023;323:592\u20137.","journal-title":"J Affect Disord"},{"issue":"7","key":"3935_CR46","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/cncr.35010","volume":"130","author":"M Agrawal","year":"2024","unstructured":"Agrawal M, Richards W, Beaussant Y, Shnayder S, Ameli R, Roddy K, et al. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer. 2024;130(7):1137\u201346.","journal-title":"Cancer"},{"key":"3935_CR47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fphar.2018.00256","volume":"9","author":"TC Malone","year":"2018","unstructured":"Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, et al. Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Front Pharmacol. 2018;9:256.","journal-title":"Front Pharmacol"},{"issue":"3","key":"3935_CR48","doi-asserted-by":"publisher","first-page":"868","DOI":"10.4314\/ahs.v17i3.30","volume":"17","author":"G Katende","year":"2017","unstructured":"Katende G, Nakimera L. Prevalence and correlates of anxiety and depression among family carers of cancer patients in a cancer care and treatment facility in uganda: a cross-sectional study. Afr Health Sci. 2017;17(3):868\u201376.","journal-title":"Afr Health Sci"},{"key":"3935_CR49","doi-asserted-by":"publisher","first-page":"101882","DOI":"10.1016\/j.ejon.2020.101882","volume":"50","author":"S Unsar","year":"2021","unstructured":"Unsar S, Erol O, Ozdemir O. Caregiving burden, depression, and anxiety in family caregivers of patients with cancer. Eur J Oncol Nurs. 2021;50:101882.","journal-title":"Eur J Oncol Nurs"},{"issue":"8","key":"3935_CR50","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.4103\/jfmpc.jfmpc_1984_21","volume":"11","author":"N Safaie","year":"2022","unstructured":"Safaie N, Zeinali H, Ghahramanfard F, Mirmohammadkhani M, Moonesan M. Anxiety and depression among new cancer patients. J Family Med Prim Care. 2022;11(8):4146\u201350.","journal-title":"J Family Med Prim Care"},{"issue":"2","key":"3935_CR51","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/pon.1568","volume":"19","author":"I Merckaert","year":"2010","unstructured":"Merckaert I, Libert Y, Messin S, Milani M, Slachmuylder JL, Razavi D. Cancer patients\u2019 desire for psychological support: prevalence and implications for screening patients\u2019 psychological needs. Psycho-Oncology: J Psychol Social Behav Dimensions Cancer. 2010;19(2):141\u20139.","journal-title":"Psycho-Oncology: J Psychol Social Behav Dimensions Cancer"},{"issue":"1","key":"3935_CR52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.31887\/DCNS.2011.13.1\/drosenstein","volume":"13","author":"DL Rosenstein","year":"2011","unstructured":"Rosenstein DL. Depression and end-of-life care for patients with cancer. Dialogues Clin Neurosci. 2011;13(1):101\u20138.","journal-title":"Dialogues Clin Neurosci"},{"key":"3935_CR53","doi-asserted-by":"publisher","unstructured":"Ratcliffe M, 574Depression and the Phenomenology of Free Will. 2013 [cited 10\/13\/2023]. In: The Oxford Handbook of Philosophy and Psychiatry [Internet]. Oxford University Press, [cited 10\/13\/2023]; [0]. Available from: https:\/\/doi.org\/10.1093\/oxfordhb\/9780199579563.013.0036","DOI":"10.1093\/oxfordhb\/9780199579563.013.0036"},{"issue":"5","key":"3935_CR54","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of Psilocybin-Assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry. 2021;78(5):481\u20139.","journal-title":"JAMA Psychiatry"},{"issue":"18","key":"3935_CR55","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-Dose psilocybin for a Treatment-Resistant episode of major depression. N Engl J Med. 2022;387(18):1637\u201348.","journal-title":"N Engl J Med"},{"issue":"4","key":"3935_CR56","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/inm.13127","volume":"32","author":"M Crowe","year":"2023","unstructured":"Crowe M, Manuel J, Carlyle D, Lacey C. Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis. Int J Ment Health Nurs. 2023;32(4):1025\u201337.","journal-title":"Int J Ment Health Nurs"},{"issue":"5","key":"3935_CR57","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5498\/wjp.v13.i5.182","volume":"13","author":"LN Fonseka","year":"2023","unstructured":"Fonseka LN, Woo BK. Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review. World J Psychiatry. 2023;13(5):182\u201390.","journal-title":"World J Psychiatry"},{"key":"3935_CR58","doi-asserted-by":"crossref","unstructured":"Dawood Hristova JJ, P\u00e9rez-Jover V. Psychotherapy with psilocybin for depression: systematic review. Behav Sci (Basel). 2023;13(4).","DOI":"10.3390\/bs13040297"},{"key":"3935_CR59","doi-asserted-by":"crossref","unstructured":"Turkia M. Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin \u2013 a retrospective case study2022.","DOI":"10.31234\/osf.io\/t6k9b"},{"issue":"5","key":"3935_CR60","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/10503307.2022.2147035","volume":"33","author":"O Fern\u00e1ndez","year":"2023","unstructured":"Fern\u00e1ndez O, Altimir C, Reinel M, Duarte J, Krause M. I am strong and I can get on with my life: the subjective experience of recovery of patients treated for depression. Psychother Res. 2023;33(5):625\u201339.","journal-title":"Psychother Res"},{"issue":"5","key":"3935_CR61","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients\u2019 accounts of increased connectedness and acceptance after psilocybin for treatment-resistant depression. J Humanistic Psychol. 2017;57(5):520\u201364.","journal-title":"J Humanistic Psychol"},{"key":"3935_CR62","unstructured":"Karp DA. Speaking of sadness: Depression, disconnection, and the meanings of illness. Oxford University Press; 2017."},{"key":"3935_CR63","doi-asserted-by":"publisher","first-page":"928186","DOI":"10.3389\/fpsyg.2022.928186","volume":"13","author":"L Osler","year":"2022","unstructured":"Osler L. An illness of isolation, a disease of disconnection: depression and the erosion of we-experiences. Front Psychol. 2022;13:928186.","journal-title":"Front Psychol"},{"key":"3935_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jcbs.2019.07.003","volume":"13","author":"T Ii","year":"2019","unstructured":"Ii T, Sato H, Watanabe N, Kondo M, Masuda A, Hayes SC, et al. Psychological flexibility-based interventions versus first-line psychosocial interventions for substance use disorders: systematic review and meta-analyses of randomized controlled trials. J Context Behav Sci. 2019;13:109\u201320.","journal-title":"J Context Behav Sci"},{"issue":"3","key":"3935_CR65","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1556\/2054.2021.00176","volume":"5","author":"P Mangini","year":"2022","unstructured":"Mangini P, Averill LA, Davis AK. Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among united States special operations forces veterans. J Psychedelic Stud. 2022;5(3):149\u201355.","journal-title":"J Psychedelic Stud"},{"key":"3935_CR66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcbs.2019.11.004","volume":"15","author":"AK Davis","year":"2020","unstructured":"Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Context Behav Sci. 2020;15:39\u201345.","journal-title":"J Context Behav Sci"},{"issue":"11","key":"3935_CR67","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1007\/s00213-022-06187-5","volume":"239","author":"R Watts","year":"2022","unstructured":"Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, et al. The watts connectedness scale: a new scale for measuring a sense of connectedness to self, others, and world. Psychopharmacology. 2022;239(11):3461\u201383.","journal-title":"Psychopharmacology"},{"key":"3935_CR68","doi-asserted-by":"crossref","unstructured":"Guss J, Krause R, Sloshower J. The Yale manual for psilocybin-assisted therapy of depression (using acceptance and commitment therapy as a therapeutic frame). 2020.","DOI":"10.31234\/osf.io\/u6v9y"},{"issue":"9752","key":"3935_CR69","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","volume":"376","author":"DJ Nutt","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376(9752):1558\u201365.","journal-title":"Lancet"},{"issue":"10","key":"3935_CR70","doi-asserted-by":"publisher","first-page":"e066019","DOI":"10.1136\/bmjopen-2022-066019","volume":"12","author":"ME Jensen","year":"2022","unstructured":"Jensen ME, Stenb\u00e6k DS, Juul TS, Fisher PM, Ekstr\u00f8m CT, Knudsen GM, et al. Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM trip Trial). BMJ Open. 2022;12(10):e066019.","journal-title":"BMJ Open"},{"issue":"1","key":"3935_CR71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/02698811231200019","volume":"38","author":"OR Hovmand","year":"2024","unstructured":"Hovmand OR, Poulsen ED, Arnfred S. Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. J Psychopharmacol. 2024;38(1):19\u201332.","journal-title":"J Psychopharmacol"},{"issue":"9","key":"3935_CR72","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1177\/0269881115598338","volume":"29","author":"PS Hendricks","year":"2015","unstructured":"Hendricks PS, Johnson MW, Griffiths RR. Psilocybin, psychological distress, and suicidality. J Psychopharmacol. 2015;29(9):1041\u20133.","journal-title":"J Psychopharmacol"},{"key":"3935_CR73","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1590\/S1677-5538.IBJU.2014.05.06","volume":"40","author":"R Taoka","year":"2014","unstructured":"Taoka R, Matsunaga H, Kubo T, Suzuki T, Yamamoto S. Impact of trait anxiety on psychological well-being in men with prostate cancer. Int Braz J Urol. 2014;40:620\u20136.","journal-title":"Int Braz J Urol"},{"key":"3935_CR74","doi-asserted-by":"publisher","first-page":"1076459","DOI":"10.3389\/fpsyt.2022.1076459","volume":"13","author":"MI Husain","year":"2023","unstructured":"Husain MI, Ledwos N, Fellows E, Baer J, Rosenblat JD, Blumberger DM, et al. Serotonergic psychedelics for depression: what do we know about Neurobiological mechanisms of action? Front Psychiatry. 2023;13:1076459.","journal-title":"Front Psychiatry"},{"issue":"1","key":"3935_CR75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40263-021-00877-y","volume":"36","author":"S Ling","year":"2022","unstructured":"Ling S, Ceban F, Lui LMW, Lee Y, Teopiz KM, Rodrigues NB, et al. Molecular mechanisms of psilocybin and implications for the treatment of depression. CNS Drugs. 2022;36(1):17\u201330.","journal-title":"CNS Drugs"},{"issue":"4","key":"3935_CR76","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cpt.2487","volume":"111","author":"AM Becker","year":"2022","unstructured":"Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, et al. Acute effects of psilocybin after Escitalopram or placebo pretreatment in a randomized, double-blind, placebo\u2010controlled, crossover study in healthy subjects. Clin Pharmacol Ther. 2022;111(4):886\u201395.","journal-title":"Clin Pharmacol Ther"},{"key":"3935_CR77","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","volume":"228","author":"BJ Catlow","year":"2013","unstructured":"Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J. Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res. 2013;228:481\u201391.","journal-title":"Exp Brain Res"},{"key":"3935_CR78","doi-asserted-by":"crossref","unstructured":"Nkadimeng SM, Steinmann CM, Eloff JN. Anti-inflammatory effects of four psilocybin-containing magic mushroom water extracts in vitro on 15-lipoxygenase activity and on lipopolysaccharide-induced cyclooxygenase-2 and inflammatory cytokines in human U937 macrophage cells. J Inflamm Res. 2021:3729\u201338.","DOI":"10.2147\/JIR.S317182"},{"key":"3935_CR79","doi-asserted-by":"publisher","first-page":"115349","DOI":"10.1016\/j.psychres.2023.115349","volume":"327","author":"O Simonsson","year":"2023","unstructured":"Simonsson O, Carlbring P, Carhart-Harris R, Davis AK, Nutt DJ, Griffiths RR, et al. Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis. Psychiatry Res. 2023;327:115349.","journal-title":"Psychiatry Res"},{"issue":"1","key":"3935_CR80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jpm.12850","volume":"30","author":"M Crowe","year":"2023","unstructured":"Crowe M, Inder M, McCall C. Experience of antidepressant use and discontinuation: A qualitative synthesis of the evidence. J Psychiatr Ment Health Nurs. 2023;30(1):21\u201334.","journal-title":"J Psychiatr Ment Health Nurs"},{"issue":"2","key":"3935_CR81","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE, Psychedelics. Pharmacol Rev. 2016;68(2):264\u2013355.","journal-title":"Pharmacol Rev"},{"key":"3935_CR82","doi-asserted-by":"crossref","unstructured":"Canal CE. Serotonergic psychedelics: experimental approaches for assessing mechanisms of action. New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology. 2018:227\u2009\u2013\u200960.","DOI":"10.1007\/164_2018_107"},{"key":"3935_CR83","doi-asserted-by":"crossref","unstructured":"Romach EA, Nachliely M, Moran O, Brami M, Lamensdorf I. Cannabinoids is a No-Go while a cancer patient is on immunotherapy; but is it safe to use psychedelics during cancer immunotherapy? BioRxiv. 2021:2021.02.01.429102.","DOI":"10.1101\/2021.02.01.429102"},{"issue":"12","key":"3935_CR84","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/medethics-2020-106070","volume":"47","author":"WR Smith","year":"2021","unstructured":"Smith WR, Sisti D. Ethics and ego dissolution: the case of psilocybin. J Med Ethics. 2021;47(12):807\u201314.","journal-title":"J Med Ethics"},{"issue":"7","key":"3935_CR85","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/02698811231180276","volume":"37","author":"OR Hovmand","year":"2023","unstructured":"Hovmand OR, Poulsen ED, Arnfred S, Storeb\u00f8 OJ. Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. J Psychopharmacol. 2023;37(7):649\u201359.","journal-title":"J Psychopharmacol"},{"key":"3935_CR86","doi-asserted-by":"crossref","unstructured":"Kiraga MK, Kuypers KPC, Uthaug MV, Ramaekers JG, Mason NL. Decreases in state and trait anxiety Post-psilocybin: A Naturalistic, observational study among retreat attendees. Front Psychiatry. 2022;13.","DOI":"10.3389\/fpsyt.2022.883869"}],"container-title":["BMC Psychology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40359-025-03935-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40359-025-03935-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40359-025-03935-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:04:32Z","timestamp":1770044672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40359-025-03935-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3935"],"URL":"https:\/\/doi.org\/10.1186\/s40359-025-03935-y","relation":{},"ISSN":["2050-7283"],"issn-type":[{"value":"2050-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}